Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by
Aged
Choline
/ analogs & derivatives
Combined Modality Therapy
Gallium Isotopes
Gallium Radioisotopes
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
/ blood
Positron Emission Tomography Computed Tomography
/ methods
Prostate-Specific Antigen
/ blood
Prostatectomy
/ methods
Prostatic Neoplasms
/ blood
Radiopharmaceuticals
Retrospective Studies
Biochemical recurrence
Choline PET/CT
Mapping of recurrence
PSMA PET/CT
Prostate cancer
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
06
02
2020
accepted:
21
04
2020
pubmed:
18
5
2020
medline:
23
7
2021
entrez:
18
5
2020
Statut:
ppublish
Résumé
Salvage radiotherapy (RT) (± androgen deprivation therapy (ADT)) is often used as a treatment in patients with biochemical recurrence (BCR) following radical prostatectomy (RP). Unfortunately, even after RT ± ADT, a significant number of patients will develop 'second' BCR. The aim of this study was to investigate the impact of postoperative treatments (adjuvant/salvage radiotherapy (RT) ± androgen deprivation therapy) on the recurrence pattern in patients with BCR following RP assessed by 11C-Choline PET/CT or 68 Ga-PSMA PET/CT. Patients who developed BCR following RP and who had at least one positive lesion on PET/CT were retrospectively assessed. Positive spots were mapped as local, lymph node (LN), skeletal or visceral recurrence. A distinction was made between locoregional (prostate bed and pelvic LN) and extrapelvic recurrence (skeletal, visceral and/or extrapelvic LN). Patients were categorized according to postoperative treatment received in three subgroups (RT, ADT and RT + ADT) and compared with the reference group (RP only). The impact of the radiation field was also investigated. We identified 200 patients assessed by Post-prostatectomy treatments (ADT and/or RT) and the postoperative radiation field (prostate bed vs. prostate bed + pelvis) have a significant impact on the recurrence pattern. This knowledge can help clinicians to counsel their patients on their chances of being eligible for (locoregional) metastasis-directed therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Salvage radiotherapy (RT) (± androgen deprivation therapy (ADT)) is often used as a treatment in patients with biochemical recurrence (BCR) following radical prostatectomy (RP). Unfortunately, even after RT ± ADT, a significant number of patients will develop 'second' BCR. The aim of this study was to investigate the impact of postoperative treatments (adjuvant/salvage radiotherapy (RT) ± androgen deprivation therapy) on the recurrence pattern in patients with BCR following RP assessed by 11C-Choline PET/CT or 68 Ga-PSMA PET/CT.
METHODS
METHODS
Patients who developed BCR following RP and who had at least one positive lesion on PET/CT were retrospectively assessed. Positive spots were mapped as local, lymph node (LN), skeletal or visceral recurrence. A distinction was made between locoregional (prostate bed and pelvic LN) and extrapelvic recurrence (skeletal, visceral and/or extrapelvic LN). Patients were categorized according to postoperative treatment received in three subgroups (RT, ADT and RT + ADT) and compared with the reference group (RP only). The impact of the radiation field was also investigated.
RESULTS
RESULTS
We identified 200 patients assessed by
CONCLUSION
CONCLUSIONS
Post-prostatectomy treatments (ADT and/or RT) and the postoperative radiation field (prostate bed vs. prostate bed + pelvis) have a significant impact on the recurrence pattern. This knowledge can help clinicians to counsel their patients on their chances of being eligible for (locoregional) metastasis-directed therapies.
Identifiants
pubmed: 32417995
doi: 10.1007/s00345-020-03220-0
pii: 10.1007/s00345-020-03220-0
doi:
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
Radiopharmaceuticals
0
gallium 68 PSMA-11
0
methyl carbon-11 choline
0
Prostate-Specific Antigen
EC 3.4.21.77
Choline
N91BDP6H0X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
399-406Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
doi: 10.3322/caac.21492
Roehl KA, Han M, Ramos CG, Ann JO, Antenor V, Catalona WJ (2004) Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172:910–914
doi: 10.1097/01.ju.0000134888.22332.bb
Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA, Kupelian P (2006) Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology 68(3):593–598
doi: 10.1016/j.urology.2006.03.075
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al (2006) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. J Urol 175(2):564
doi: 10.1016/S0022-5347(05)00388-5
Mottet N, Bellmunt, Briers E, Bolla M, Bourke L (2018) EAU–ESTRO–ESUR–SIOG Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Copenhagen 2018, pp 1–145
Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB et al (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61(3):607–611
doi: 10.1016/S0090-4295(02)02411-1
Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q et al (2015) Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 56(8):1185–1190
doi: 10.2967/jnumed.115.160382
Grubmüller B, Baltzer P, D’andrea D, Korn S, Haug AR, Hacker M, et al (2018) 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy—diagnostic performance and impact on therapeutic decision-making. Eur J Nucl Med Mol Imaging 45:235–242
doi: 10.1007/s00259-017-3858-2
Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N et al (2018) 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med 59(2):230–237
doi: 10.2967/jnumed.117.201749
Van den Bergh L, Lerut E, Haustermans K, Deroos CM, Oyen R, Isebaert S, Budiharto T, Ameye F, Mottaghy FM, Bogaerts K, Van Poppel H, Joniau S (2015) Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Urol Oncol Semin Orig Investig 33(3):109.e23–109.e31
Sobol I, Zaid HB, Haloi R, Mynderse LA, Froemming AT, Lowe VJ et al (2017) Contemporary mapping of post-prostatectomy prostate cancer relapse with 11C-choline positron emission tomography and multiparametric magnetic resonance imaging. J Urol 197(1):129–134
doi: 10.1016/j.juro.2016.07.073
Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW et al (2013) Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 24(11):2881–2886
doi: 10.1093/annonc/mdt335
Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I et al (2016) Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17(6):747–756
doi: 10.1016/S1470-2045(16)00111-X
Rauscher I, Maurer T, Beer AJ, Graner F-P, Haller B, Weirich G et al (2016) Value of 68 Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy Original Research. J Nucl Med 57(11):1713–1719
doi: 10.2967/jnumed.116.173492
Draulans C, Joniau S, Fonteyne V, Delrue L, Decaestecker K, Everaerts W et al (2018) Benefits of elective para-aortic radiotherapy for pN1 prostate cancer using arc therapy (intensity-modulated or volumetric modulated arc therapy): protocol for a nonrandomized phase II trial. JMIR Res Protoc 7(12):e11256
doi: 10.2196/11256
Nehra A, Parker WP, Haloi R, Park SS, Mynderse LA, Lowe VJ et al (2018) Identification of recurrence sites following post-prostatectomy treatment for prostate cancer using 11C-choline positron emission tomography and multiparametric pelvic magnetic resonance imaging. J Urol 199(3):726–733
doi: 10.1016/j.juro.2017.09.033
Jorgensen TJ (2009) Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther 8(8):665–670
doi: 10.4161/cbt.8.8.8304
Abdollah F, Suardi N, Cozzarini C, Gallina A, Capitanio U, Bianchi M et al (2013) Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 63(6):998–1008
doi: 10.1016/j.eururo.2012.10.036
Bellomo R, Warrillow SJ, Reade MC (2009) Why we should be wary of single-center trials. Crit Care Med 37(12):3114–3119
doi: 10.1097/CCM.0b013e3181bc7bd5
Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K et al (2017) Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging 44(1):92–101
doi: 10.1007/s00259-016-3490-6
Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S et al (2016) 68 Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18 F-choline-PET/CT HHS public access author manuscript. Clin Nucl Med 41(7):515–521
doi: 10.1097/RLU.0000000000001197
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG et al (2014) Comparison of PET imaging with a 68 Ga-labelled PSMA ligand and 18 F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:11–20
doi: 10.1007/s00259-013-2525-5
Devos G, De Meerleer G, Joniau S (2019) Have we entered the era of imaging before salvage treatment for recurrent prostate cancer? Eur Urol 76(3):265–267
doi: 10.1016/j.eururo.2019.04.016
De Bruycker A, Fonteyne V, Ost P (2019) Re: Gaëtan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol 2019;76:265–7. Eur Urol 76(5):e147–e148
doi: 10.1016/j.eururo.2019.06.033